肺动脉高压患者肺血管阻力与临床结局:回顾性队列研究
该回顾性队列研究分析了美国退伍军人医疗系统2007至2016年接受右心导管检查的患者,发现当平均肺动脉压≥19 mmHg且肺毛细血管楔压≤15 mmHg时,肺血管阻力≥2.2 Wood units与全因死亡和心衰住院风险增加相关,并在范德堡大学队列中验证了死亡风险比。
要点
- 肺血管阻力约2.2 Wood units起全因死亡风险即增加。
- mPAP≥19 mmHg且PAWP≤15 mmHg者,PVR≥2.2 Wood units死亡风险增高。
- 该阈值下心衰住院风险亦增加,验证队列结果一致。
核心结论
- 肺血管阻力约2.2 Wood units及以上即与肺动脉压升高患者的死亡和心衰风险增加相关。
研究设计与样本
- 验证队列来自范德堡大学医学中心1998年9月24日至2016年6月1日的右心导管队列,N=3699。
关键数值与推荐
- 风险增加见于mPAP≥19 mmHg且PAWP≤15 mmHg的患者。
临床怎么用
- 对接受右心导管检查、mPAP≥19 mmHg且PAWP≤15 mmHg的患者,应关注PVR≥2.2 Wood units带来的死亡和心衰住院风险。
局限性
- 主要队列以男性退伍军人为主,合并心肺疾病者比例高,需在合并症较少的高危人群中验证普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In pulmonary hypertension subgroups, elevated pulmonary vascular resistance (PVR) of 3·0 Wood units or more is associated with poor prognosis. However, the spectrum of PVR risk in pulmonary hypertension is not known. To address this area of uncertainty, we aimed to analyse the relationship between PVR and adverse clinical outcomes in pulmonary hypertension. METHODS: We did a retrospective cohort study of all patients undergoing right heart catheterisation (RHC) in the US Veterans Affairs health-care system (Oct 1, 2007-Sep 30, 2016). Patients were included in the analyses if data from a complete RHC and at least 1 year of follow-up were available. Both inpatients and outpatients were included, but individuals with missing mean pulmonary artery pressure (mPAP), pulmonary artery wedge pressure, or cardiac output were excluded. The primary outcome measure was time to all-cause mortality assessed by the Veteran Affairs vital status file. Cox proportional hazards models were used to assess the association between PVR and outcomes, and the mortality hazard ratio was validated in a RHC cohort from Vanderbilt University Medical Center (Sept 24, 1998-June 1, 2016). FINDINGS: The primary cohort (N=40 082; 38 751 [96·7%] male; median age 66·5 years [IQR 61·1-73·5]; median follow-up 1153 days [IQR 570-1971]), included patients with a history of heart failure (23 201 [57·9%]) and chronic obstructive pulmonary disease (13 348 [33·3%]). We focused on patients at risk for pulmonary hypertension based on a mPAP of at least 19 mm Hg (32 725 [81·6%] of 40 082). When modelled as a continuous variable, the all-cause mortality hazard for PVR was increased at around 2·2 Wood units compared with PVR of 1·0 Wood unit. Among patients with a mPAP of at least 19 mm Hg and pulmonary artery wedge pressure of 15 mm Hg or less, the adjusted hazard ratio (HR) for mortality was 1·71 (95% CI 1·59-1·84; p<0·0001) and for heart failure hospitalisation was 1·27 (1·13-1·43; p=0·0001), when comparing PVR of 2·2 Wood units or more to less than 2·2 Wood units. The validation cohort (N=3699, 1860 [50·3%] male, median age 60·4 years [49·5-69·2]; median follow-up 1752 days [IQR 1281-2999]) included 2870 patients [77·6%] with mPAP of at least 19 mm Hg (1418 [49·4%] male). The adjusted mortality HR for patients in the mPAP of 19 mm Hg or more group and with PVR of 2·2 Wood units or more and pulmonary artery wedge pressure of 15 mm or less Hg (1221 [42·5%] of 2870) was 1·81 (95% CI 1·33-2·47; p=0·0002). INTERPRETATION: These data widen the continuum of clinical risk for mortality and heart failure in patients referred for RHC with elevated pulmonary artery pressure to include PVR of around 2.2 Wood units and higher. Testing the generalisability of these findings in at-risk populations with fewer cardiopulmonary comorbidities is warranted. FUNDING: None.
引用
- Maron BA, Brittain EL, Hess E, et al. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir Med. 2020. PMID: 32730752. doi:10.1016/S2213-2600(20)30317-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。